Pharming Group stock

PHARM · Euronext Amsterdam · EUR

Compare Pharming Group
€1.08Change from previous close: −3.05%Absolute change: −€0.03

Close · November 20, 2026

Price history

−25.41% over the period

1 year: from €1.45 (November 20, 2025) to €1.08 (November 20, 2026), −25.41%.

Show chart data

Closing prices adjusted for splits: the last close of each month.

DateClose
November 20, 2026€1.08
October 30, 2026€1.09
September 30, 2026€0.89
August 31, 2026€0.99
July 31, 2026€0.88
June 30, 2026€1.20
May 29, 2026€1.15
April 30, 2026€1.43
March 31, 2026€1.43
February 27, 2026€1.39
January 30, 2026€1.71
December 31, 2025€1.43
November 28, 2025€1.44
November 20, 2025€1.45

At a glance

  • The company

    Develops and commercializes protein replacement therapies and precision medicines for rare diseases, including RUCONEST and Joenja

  • Latest results

    Quarter to September 30, 2026 · EPS $0.03 (estimate $0.02)

TickerLandia's take on Pharming Group

Analysis calculated by TickerLandia from financial statements and prices, with public rules. Not investment advice. How we analyse stocks

Where the price stands

52-wk low€0.82
52-wk high€1.82

−40.51% from the 52-week high

Analysts · 4 analysts

Average target€2.24+107.56% vs. price

Buy 4 · Hold 0 · Sell 0 · Strong buy

TickerLandia Fingerprint: Pharming Group

Compared with similar companies: high risk, high earnings stability, and low price.

Financials and price compared with 61 companies in the biotechnology industry, worldwide. Momentum and risk compared with 1,160 European stocks.

Position in the group from 0 to 100 (100 = highest value): it describes, it does not rate. Tap a row for the metrics. Calculated on November 22, 2026. An indicator calculated by TickerLandia from financial statements and market data. How it is calculated

Valuation

Pharming Group is pricier than similar companies

Pharming Group's P/E (trailing 12 months): 36.1, +145% against the median of a group of 7 similar companies (14.7).

Compared with 7 similar companies

Pharming Group's metrics compared with similar companies
MetricPharming GroupPosition in the groupBand
P/E (trailing 12 months)36.1High
Forward P/E32.2Middle
Operating margin12.8%Middle
ROE8.7%Middle
Debt/equity0.39High

Grey band: the middle half of the group; tick: the median; dot: Pharming Group. All multiples and dividends

TickerLandia analysisHow it is calculated

The financials

The business in numbers

Revenue

$90.21M

Latest quarter · Q2 2026

Net income

$1.64M

Latest quarter · Q2 2026

Quarterly net margin

1.8%

Latest quarter · Q2 2026

Numbers and valuation

Full valuation
Market cap
€765.47M
P/E
36.1
EPS
€0.03
Volume
8.02M
Daily trading
€12.81M
Dividend yield
0.00%

How Pharming Group is changing

All results
  • Revenue grew 12.1% a year on average over the last 5 years

  • Operating margin rose from 5.0% to 8.7%

  • Shares outstanding up 9.4% in 5 years

Returns

Pharming Group returns

€1,000 invested in Pharming Group 5 years ago, on November 22, 2021, would be worth €1,424 today: +42.38% in total, +7.33% per year. This is the price return only: dividends are excluded.

PeriodPharming GroupAEX€1,000 becomes
1 month+26.76%−5.95%€1,268
6 months−2.57%+3.14%€974
Year to date−24.16%+12.07%€758
1 year−25.41%+14.04%€746
3 years+0.32%+40.38%€1,003
5 years+42.38%+30.76%€1,424
10 years+377.91%+135.34%€4,779

Over the last 6 months it has done better than 14% of the stocks in the Healthcare sector.

Price only, without dividends. Calculate your investment

The chart in detail

Pharming Group: technical analysis

Pharming Group shows no clear trend: the price and its 50- and 200-session averages are not aligned. The price is 99.7% below its all-time closing high (€310.17, March 10, 2000).

Trend
No clear trend
RSI (14 sessions)
52
Between 30 and 70
vs 200-session average
−5.99%

Support and resistance

Price areas where Pharming Group has stopped several times in the last year. They describe the chart; they are not forecasts.

  1. Resistance€1.37+27.12%2 touches, last on April 28, 2026
  2. Resistance€1.27+17.88%3 touches, last on July 9, 2026
  3. Resistance€1.20+11.21%2 touches, last on November 12, 2026
  4. Last price€1.08
  5. Support€1.07−0.67%2 touches, last on November 6, 2026
  6. Support€1.01−6.40%3 touches, last on August 28, 2026
  7. Support€0.98−9.75%2 touches, last on September 22, 2026

Volatility and risk

Over the last year it has moved less than the AEX.

Beta (1 year) vs AEX
0.59
Volatility (60 sessions, annualised)
40.3%
Largest fall in the last year
−53.51%

Close of November 20, 2026. Descriptive data calculated on daily prices: it describes the chart and is not investment advice. Beta and volatility describe the last year and can change a lot from one year to the next. How we calculate it

Pharming Group: seasonality

Average monthly price change over 28 years

+11.9%Jan+3.1%Feb−8.8%Mar+0.5%Apr−1.4%May+1.4%Jun−1.0%Jul+0.0%Aug−2.7%Sep+10.1%Oct+1.1%Nov+2.0%Dec

Over the last 28 years, the strongest month for Pharming Group has been January: +11.94% on average, positive in 12 years out of 27. The weakest has been March: −8.83% on average, positive in 6 years out of 27. November, the current month, has been positive in 9 years out of 27 (+1.10% on average).

Show chart data
MonthAverageMedianPositive years
January+11.94%−3.22%12 of 27
February+3.15%−2.50%10 of 27
March−8.83%−5.81%6 of 27
April+0.46%−2.22%9 of 27
May−1.43%−3.67%8 of 27
June+1.40%−1.87%11 of 27
July−0.97%+0.05%14 of 28
August+0.04%+2.24%16 of 28
September−2.74%−4.11%9 of 28
October+10.05%−1.89%11 of 28
November+1.10%−2.95%9 of 27
December+1.96%−1.05%11 of 27

Price change only, dividends excluded. Past seasonality does not predict future moves.

The company

Pharming Group and its competitors

Pharming Group N.V. develops and commercializes protein replacement therapies and precision medicines for rare diseases, with commercial activity in the United States, Europe and other markets worldwide. Its lead product is RUCONEST, a treatment for acute attacks of hereditary angioedema in adults and adolescents. Joenja, an oral medicine for activated phosphoinositide 3-kinase delta syndrome, is the other principal product, and the company continues to develop it alongside a partnership with Novartis.

Headquarters
Leiden, Netherlands
Employees
407
Founded
1988
Chief executive
Fabrice Chouraqui
Pharming Group and its competitors
CompanyMarket capOperating marginP/E (trailing 12 months)6 months
Pharming GroupPHARM$841.25M12.8%36.1−2.57%
InventivaIVA$890.8M-5,980.9%—−33.75%
PhilogenPHIL$905.96M79.1%3.67−5.63%
Basilea PharmaceuticaBSLN$1.07B24.2%18.1+35.06%
GubraGUBRA$730.02M-73.1%—−22.24%
Pharma MarPHM$1.1B21.3%14.7−41.56%

Same industry or related industries, similar size. Compare Pharming Group with its competitors · Full profile